Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptide.

Robertson CS, Garcia R, Gaddam SS, Grill RJ, Cerami Hand C, Tian TS, Hannay HJ

Journal of neurotrauma20 Sept 2012Cited by 24 (Europe PMC)

PMID22827443PMCIDPMC3653382DOI10.1089/neu.2012.2431PepBankPUB-22827443

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with mild traumatic brain injury, pHBSP shortened the time to find the platform in the Morris water maze compared with control peptide.
In plain wordsIn rats with mild brain injury, pHBSP helped rats find the maze platform faster than the inactive control peptide.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseMorris water maze: time to find the platform
Study
ratn = 64
Mild traumatic brain injury (cortical impact)
Comparator
Inactive control peptide
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 μg/kg · intraperitoneal · Every 12 h for 3 daysAs given in this study (rat).
Measurements
Time to find platform
22.3 sec
pHBSP
Time to find platform
26.3 sec
Control
Source sentences
Summary
Treatment with pHBSP resulted in significantly improved performance on the Morris water maze task. Rats that received pHBSP required 22.3±1.3 sec to find the platform, compared to 26.3±1.3 sec in control rats (p=0.022).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-four rats were randomly assigned to pHBSP or control (inactive peptide) 30 μg/kg IP every 12 h for 3 days, starting at either 1 hour (early treatment) or 24 h (delayed treatment), after mTBI (cortical impact injury 3 m/sec, 2.5 mm deformation).
Report a problemFND-2282744301
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with mild traumatic brain injury, pHBSP shortened the distance traveled to the platform in the Morris water maze compared with control peptide.
In plain wordsIn rats with mild brain injury, pHBSP rats swam a shorter way to the maze platform than rats given the inactive control peptide.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseMorris water maze: distance traveled to the platform
Study
ratn = 64
Mild traumatic brain injury (cortical impact)
Comparator
Inactive control peptide
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 μg/kg · intraperitoneal · Every 12 h for 3 daysAs given in this study (rat).
Measurements
Distance to platform
5 meters
pHBSP
Distance to platform
6.1 meters
Control
Source sentences
Summary
The rats that received pHBSP also traveled a significantly shorter distance to get to the platform, 5.0±0.3 meters, compared to 6.1±0.3 meters in control rats (p=0.019).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-four rats were randomly assigned to pHBSP or control (inactive peptide) 30 μg/kg IP every 12 h for 3 days, starting at either 1 hour (early treatment) or 24 h (delayed treatment), after mTBI (cortical impact injury 3 m/sec, 2.5 mm deformation).
Report a problemFND-2282744302
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with mild traumatic brain injury, pHBSP had no treatment effect on motor performance.
In plain wordsIn rats with mild brain injury, pHBSP did not change movement ability compared with the inactive control peptide.
Peptide
Cibinetide (ARA-290)
Outcome
No significant changeMotor performance
Study
ratn = 64
Mild traumatic brain injury (cortical impact)
Comparator
Inactive control peptide
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
30 μg/kg · intraperitoneal · Every 12 h for 3 daysAs given in this study (rat).
Source sentences
Summary
Motor tasks were only transiently impaired in this mTBI model, and no treatment effect on motor performance was observed with pHBSP.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-four rats were randomly assigned to pHBSP or control (inactive peptide) 30 μg/kg IP every 12 h for 3 days, starting at either 1 hour (early treatment) or 24 h (delayed treatment), after mTBI (cortical impact injury 3 m/sec, 2.5 mm deformation).
Report a problemFND-2282744303
04AnimalAnimal study (in vivo)Mechanism
In rats with mild traumatic brain injury, pHBSP reduced the activation of CD68-labeled inflammatory cells.
In plain wordsIn rats with mild brain injury, pHBSP reduced the activation of inflammatory cells in the brain.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseCD68-labeled inflammatory cell activation
Study
ratn = 64
Mild traumatic brain injury (cortical impact)
Comparator
Inactive control peptide
Outcome group
Inflammation markers · Nervous system and cognition
Studied dose
30 μg/kg · intraperitoneal · Every 12 h for 3 daysAs given in this study (rat).
Source sentences
Summary
Despite the minimal tissue injury with this mTBI model, there was significant activation of inflammatory cells identified by labeling with CD68, which was reduced in the pHBSP-treated animals.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-four rats were randomly assigned to pHBSP or control (inactive peptide) 30 μg/kg IP every 12 h for 3 days, starting at either 1 hour (early treatment) or 24 h (delayed treatment), after mTBI (cortical impact injury 3 m/sec, 2.5 mm deformation).
Report a problemFND-2282744304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.